Oncology Letters Special Issues

Clinical and Molecular Insights on Urothelial Carcinoma

Lead Editor:

    Dr Chien-feng Li
    Chi-Mei Medical Center
    Taiwan

Urothelial carcinomas (UCs) are one of the most common malignant tumors worldwide, they arise from the upper urinary tracts and lower urinary tracts. Urinary bladder urothelial carcinoma (UBUC) is the most prevalent among the UCs (90%-95%). Upper tract urothelial carcinomas (UTUCs) are relatively rare compared with UBUCs and only account for 5-10% of UCs in Western countries but demonstrate an unusual high prevalence in some regions. At molecular level, UCs are driven by two different genetic pathways that form noninvasive low-grade papillary carcinoma and high-grade non-invasive/invasive carcinomasm respectively. The mutation of FGFR3, HRAS and PIK3CA involved in the MAPK and PI3K pathways are associated with the growth of non-invasive low-grade papillary urothelial carcinomas. While Deficiency of TP53 and retinoblastoma 1 (RB) related to cell cycle regulation at the G1/S checkpoint usually occurs in high-grade in situ and invasive carcinomas. Although some genetic hallmarks have been disclosed for urothelial carcinogenesis, the underlying mechanism responsible for urothelial carcinoma initiation and progression remains largely unknown. Moreover, there are relatively limited therapeutics for UCs. In spite of the development of immunotherapy and fibroblast growth factor receptors-2 and -3 targeted therapy, surgery remains to be the mainstay of early-stage UCs; chemotherapy and experimental therapies remain the therapeutic cornerstone in unresectable and metastatic UCs. Accordingly, it is mandatory to collect more molecular, translational, and clinical insights on UCs for further theranostic adjuncts.


Update on gynecologic surgery in benign and oncologic disease

Lead Editor:

    Professor Stefano Cianci
    University of Messina
    Italy

Gynecologic surgery is in continuous development. New technologies and new techniques are actually available from endoscopy to robotic both in oncology and benign pathology. The applications are different allowing to obtain better surgical dexterity, imaging and invasiveness reduction. This focused issue is aimed to give an overview and an update on novelties in gynecologic surgery


Natural Products: Recent Therapeutic Advances in Oncology Research

Lead Editor:

    Professor Mourad A. M. Aboul-Soud
    Chair of Medical and Molecular Genetics Research, Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh 11433
    Saudi Arabia

Despite significant progress made towards discovery of potent chemotherapeutic agents, cancer remains an aggressive and devastating disease, being the second-leading cause of mortalities worldwide. Currently, therapeutic protocols employed to treat cancers primarily rely on three traditional strategies including surgery, chemotherapy and radiotherapy. The intrinsic non-target toxicity to normal cells of the repertoire of chemotherapeutic anticancer drugs utilized in clinical settings is considered a limitation. Alternatively, natural products (NPs) have been shown to be effective as anticancer drugs with a wider safety margin and minimal side effects. The primary focus of this special issue is therefore to invite submissions of original articles and reviews tackling the discovery of NPs isolated from various terrestrial and marine sources with potential anticancer activities and the elucidation of their mechanism-of-action. Studies employing in vitro cancer cell lines and in vivo non-human primate models are welcome provided that they are appropriately-designed to include non-cancerous and positive controls. Research on natural extracts/fractions must incorporate full chemical characterization of their constituents. Articles dealing with the cytotoxicity of green-synthesized nanoparticles such as metal, metal oxide and polymeric nanocomposites are also welcome contingent on including mechanistic insights. Work on naturally-derived synthetic analogues or congeners with enhanced efficacy is also considered.


Journal Cover

September-2022
Volume 24 Issue 3

Print ISSN: 1792-1074
Online ISSN: 1792-1082

Sign up for eToc alerts

Recommend to Library

Full Size Image